Synageva BioPharma (GEVA -5.5%) slips today after JP Morgan cut the shares to Neutral and lowers its price target from $57 to $50. The firm cites concerns over enrollment challenges related to its ongoing Phase 3 trial of sebelipase alfa in late-onset LAL Deficiency, saying that awareness of the disease is fairly low, even among specialists, so patient identification could take a bit longer.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs